MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oxford Nanopore Technologies

Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
From Oxford Nanopore Technologies
Via Business Wire
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
From Oxford Nanopore Technologies
Via Business Wire
Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore and UK Biobank to create world’s first epigenetic dataset targeting the causes of cancer, dementia, complex disease
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Announces Landmark UK Government Partnership to Advance Genomics-Driven Healthcare Innovation in the UK
From Oxford Nanopore Technologies
Via Business Wire
Singapore’s National Precision Medicine (NPM) Programme Engages Oxford Nanopore to Advance Understanding of the Genetics of Singapore’s Multi-Ethnic Population
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Technologies and Plasmidsaurus Announce Strategic Collaboration to Advance Plasmid Sequencing
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore launches PromethION 2 Integrated into open early access
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Technologies and Fabric Genomics Collaborate to Launch an Integrated Whole-Genome Sequencing Solution to Advance the Future of Paediatric Patient Care
From Oxford Nanopore Technologies
Via Business Wire
Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders
From Oxford Nanopore Technologies
Via Business Wire
The University of Queensland and Oxford Nanopore Technologies Team up to Accelerate Research Into Quality Control Testing for mRNA Vaccines
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore announces education collaboration with Cold Spring Harbor DNA Learning Center and launches pilot accessible sequencing education programme
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore and 4bases Announce Collaboration to Combine Nanopore Sequencing Devices and 4bases Kits to Support Rapid, High-accuracy Analyses in Human and Cancer Genetics, with a First Target of Same-day BRCA1 and BRCA2 Analysis
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Technologies Teams up With UPS Healthcare to Accelerate Delivery of New-Generation DNA Sequencing Technology to More Customers in Locations Across Asia Pacific
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Technology Update Shows Consolidations and Updates for a Single, High-performance Sequencing Platform
From Oxford Nanopore Technologies
Via Business Wire
Oxford Nanopore Opens Genomics Market With PromethION 2 Solo: The World’s First Portable, High Yield Sequencer Providing Comprehensive DNA Analysis for Anyone, Anywhere
From Oxford Nanopore Technologies
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story